Lung adenocarcinoma is a markedly heterogeneous entity characterized by various histologic subtypes as well as clinically relevant oncogenic driver mutations. Since the release of the new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS)[@b1], many studies have investigated the possible correlations among predominant adenocarcinoma subtype, driver mutations and patient prognosis[@b2][@b3][@b4][@b5][@b6][@b7][@b8][@b9].

Solid predominant lung adenocarcinoma were reported to be associated with aggressive clinicopathologic features, including larger tumor size at presentation, lymph node metastasis as well as lymphovascular and pleural invasion[@b6][@b10][@b11][@b12]. It is reported that solid pattern is a poor prognostic factor in lung adenocarcinoma[@b2][@b4][@b6][@b8][@b12][@b13]. However, the predictive value of solid pattern for chemotherapy/radiotherapy remains poorly defined[@b2][@b3][@b7]. A recent study also suggested that solid subtype was a negative predictor of response to EGFR tyrosine kinase inhibitor (TKI) treatment[@b14].

In this study, we performed a comprehensive analysis of solid predominant lung adenocarcinoma regarding clincopathologic characteristics, molecular status, and most importantly, the prognostic and predictive value.

Results
=======

A total of 186 solid predominant lung adenocarcinoma patients were included in this study, along with 522 acinar predominant, 143 papillary predominant, 113 lepidic predominant, 20 micropapillary predominant, 2 enteric predominant and 53 invasive mucinous adenocarcinoma. There were 481 male patients and 558 female patients. The median age was 60 years old, with a range of 22 to 84 years. The number of cases in stages I, II and III were 580, 146 and 313, respectively ([Table 1](#t1){ref-type="table"}).

Solid predominant adenocarcinoma was significantly correlated with male gender (*P* \< 0.001), younger age at diagnosis (*P* = 0.049) and smoking history (*P* \< 0.001). More solid subtype patients underwent resections greater than lobectomy (bi-lobectomy or pneumonectomy). Solid subtype adenocarcinoma was significantly associated with aggressive tumor characteristics including larger tumor size (*P* \< 0.001), higher prevalence of lymphovascular invasion (*P* \< 0.001) and lymph node metastasis (*P* \< 0.001), and more advanced disease stage (*P* \< 0.001) ([Table 1](#t1){ref-type="table"}).

Compared to other histologic subtypes, solid predominant adenocarcinoma harbored significantly lower frequency of *EGFR* mutations (38.2% vs. 66.8%, *P* \< 0.001), but higher prevalence of *KRAS* mutations (12.4% vs. 6.1%, *P* = 0.003) and *RET* fusions (3.2% vs. 0.8%, *P* = 0.017). Significantly higher proportion of solid predominant adenocarcinomas were "pan-negative" for these 7 common driver mutations (37.6% vs. 17.8%, *P* \< 0.001) ([Table 1](#t1){ref-type="table"}).

To ensure a sufficient follow up, we included 442 patients diagnosed between October 2007 and March 2011 for survival analysis. The patient cohort were comprised of 94 solid predominant, 211 acinar predominant, 75 papillary predominant, 36 lepidic predominant, 8 micropapillary predominant, 2 enteric predominant, and 16 invasive mucinous adenocarcinoma.

In univariate analysis, solid predominant adenocarcinoma patients had significantly worse RFS (*P* \< 0.001) and OS (*P* \< 0.001) than non-solid subtype ([Figure 1A and 1B](#f1){ref-type="fig"}). A total of 63 solid subtype and 155 non-solid subtype patients experienced disease recurrence. When comparing pattern of recurrence, we found that distant recurrence was more likely to occur in solid predominant adenocarcinoma (82.5% vs. 66.5%, *P* = 0.018).

When the survival analysis was limited to stage II-III patients ([Figure 1E and 1F](#f1){ref-type="fig"}), the survival difference between solid and non-solid subtype was still significant regarding RFS (*P* = 0.011) and OS (*P* = 0.001). When stage II and stage III patients were analyzed separately, solid predominant lung adenocarcinoma patients had significantly worse OS in both category (*P* = 0.019 for stage II; *P* = 0.031 for stage III). However, statistical significance was not achieved when comparing RFS (*P* = 0.206) or OS (*P* = 0.498) in stage I patients ([Figure 1C and 1D](#f1){ref-type="fig"}).

In multivariate survival analysis incorporating gender, age, smoking history, lymphovascular invasion, pathologic stage (stage II/III vs. stage I), histologic subtype and mutational status ([Table 2](#t2){ref-type="table"}), solid subtype was an independent predictor of poor OS (OR = 1.876, 95% CI: 1.291--3.158; *P* = 0.003).

As the application of postoperative adjuvant chemotherapy in stage I NSCLC remains controversial, we therefore investigated the predictive value of solid subtype for stage II-III adenocarcinoma patients who received adjuvant chemotherapy. In univariate analysis ([Figure 1G and 1H](#f1){ref-type="fig"}), solid subtype was significantly associated with worse RFS (*P* = 0.015) and OS (*P* = 0.001).

In multivariate survival analysis adjusting for gender, age, smoking history, lymphovascular invasion, pathologic stage (stage III vs. stage II), histologic subtype and mutational status ([Table 2](#t2){ref-type="table"}), solid subtype also proved to be an independent predictor of poor OS (OR = 2.020, 95% CI: 1.291--3.158; *P* = 0.002).

In univariate analysis ([Figure 2](#f2){ref-type="fig"}), solid subtype patients had significantly worse PRS than non-solid predominant adenocarcinoma patients (*P* = 0.010). However, pathologic stage and *EGFR* mutational status, but not solid histology, were independent predictors of PRS as demonstrated in multivariate analysis ([Table 2](#t2){ref-type="table"}).

Of the 442 invasive lung adenocarcinoma patients diagnosed between October 2007 and March 2011, eight *EGFR*-mutated solid predominant lung adenocarcinoma patients received EGFR TKIs (gefitinib or erlotinib) after disease recurrence. Detailed information was listed in [Table 3](#t3){ref-type="table"}. There were three partial response (PR), two stable disease (SD) and three progressive disease (PD). The objective response rate was 37.5%.

The NF1 mRNA expression was analyzed in 571 lung adenocarcinoma samples harboring classic *EGFR* mutations including exon 19 deletions and L858R as well as normal lung tissues. Low expression level of NF1 was found in 33 out of 65 (50.8%) solid predominant adenocarcinomas and 315 out of 506 (62.3%) non-solid predominant tumors. There was no significant correlation between solid predominant tumors and NF1 expression (*P* = 0.074).

Discussion
==========

The correlations among the histologic subtype of lung adenocarcinoma, the status of common driver mutations, patient prognosis and the predictive value for TKIs as well as cytotoxic chemotherapy treatment have recently been investigated worldwide to optimize the treatment strategy for this disease. In this study, we reviewed a large sample of completely resected invasive lung adenocarcinoma to have a comprehensive assessment of the clinicopathologic characteristics, mutational status, patterns of recurrence, RFS, OS and PRS associated with solid predominant adenocarcinoma as well as its predictive value for postoperative adjuvant chemotherapy and EGFR TKIs after recurrence.

Consistent with previous studies[@b6][@b10][@b11][@b12], we also found that solid predominant adenocarcinoma patients were more likely to be males and ever smokers, and were characterized by more advanced TNM stage. Molecularly, solid subtype adenocarcinomas were negatively associated with *EGFR* mutations, while positively correlated with *KRAS* mutations and *RET* fusions. More than one third (37.6%) of solid predominant lung adenocarcinoma could not be defined by any of the seven common driver mutations, about twice the proportion of other invasive adenocarcinoma subtypes. More attention should be paid to this aggressive lung adenocarcinoma subtype to identify new molecular targets.

Our study showed that patients with solid predominant adenocarcinomas were more likely to have initial distant recurrences than non-solid invasive adenocarcinomas. This result is in consistence with a previous study by Hung and colleagues[@b2], probably due to the more aggressive behavior of solid subtype.

The poor prognostic role of solid histology has been reported by several previous studies[@b2][@b4][@b6][@b8][@b10][@b12][@b13]. We further showed that solid subtype was an independent poor prognostic marker by multivariate survival analysis incorporating clinicopathologic variables as well as status of well-identified driver mutations. When the survival analysis was stratified by pathologic stage, we found that solid subtype was associated with shorter RFS and OS in stage II-III patients, but not in stage I patients. One explanation is that in this study, we excluded AIS and MIA which are usually classified as stage I and have extremely good prognosis according to previous studies[@b8][@b15]. The relatively small number of stage I solid predominant adenocarcinoma patients and the short follow up is another possible explanation. Finally, as postoperative adjuvant chemotherapy was routinly recommended for stage II-III paitnets who could tolerate, the survival difference between solid and non-solid subtype might be enlarged if solid predominant adencarcinomas were relatively insensitive to cytotoxic chemotherapy.

The predictive value of solid subtype for adjuvant chemotherapy/radiotherpay remains controversial[@b2][@b3][@b7]. In a German cohort of 500 stage I-IV resected lung adenocarcinomas, the authors found that solid predominant adenocarcinoma patients had improved prognosis with adjuvant radiotherapy[@b7]. In a Mexico cohort of 313 stage IIIB-IV lung adenocarcinoma, Campos-Parra and collegues[@b3] revealed that high-grade lung adenocarcinoma (solid, micropapillary and papillary-predomiannt) patients had better response rates, progression-free survival and overall survival than lepidic and acinar-predomiannt adenocarcinoma patients when treated with platinum-based chemotherapy. However, a recent study of an Asian cohort of 573 stage I-III lung adenocarcinoma patients reported that solid predominant adenocarcinoma was a poor predictor in patients undergoing adjuvant chemotherapy[@b2]. In this study, we performed multivariate survival analysis of stage II-III patients who received postoperative adjuvant chemotherapy, and found that solid subtype was an independent predictor of poor OS.

We further showed that solid predominant adencarcinoma was significantly correlated with poor post-recurrence survival in univariate analysis. However, multivariate analysis revealed that more advanced disease stage and wild-type *EGFR* mutational status, rather than solid histology, were independent predictors of poor PRS, indicating that the poor PRS of patients with solid predominant might be in part due to the relatively lower frequency of *EGFR* mutations in this histologic subtype and therefore less opportunity to receive targeted therapies. Yoshida and colleagues[@b14] reported that solid predominant histology was negatively associated with response to EGFR TKIs in *EGFR*-mutated lung adenocarcinoma patients compared to other histologic subtypes (response rate: 61% vs. 88%, *P* = 0.03). In this study, we observed a response rate of only 37.5% (3/8), while a PD rate of 37.5% (3/8) in *EGFR*-mutated solid predominant lung adenocarcinoma patients with recurrent diesease. However, the number of patients is still too small to draw a definite conclusion.

A recent study revealed that low expression level of NF1 was correlated with primary and acquired resistance of lung adenocarcinms to EGFR TKIs[@b16]. In 2014, the Cancer Genome Atlas Research Network released the comprehensive molecular profiling of 230 lung adenocarcinomas. One of their findings was that the proximal-inflammatory subtype of lung adenocarcinoma, which was charaterized by solid histopathology, was associated with loss-of-function mutations of NF1[@b17]. However, we did not find a significant association between solid subtype and NF1 expression, suggesting that the expression level of NF1 might not be responsible for the relatively poor response to EGFR TKIs of solid predominant lung adenocarcinoma patients harboring *EGFR* mutations.

In conclusion, solid subtype was an independent poor prognostic factor and an independent negative predictor for adjuvant chemotherapy in invasive lung adenocarcinoma patients undergoing radical resection. In addition to the relatively lower frequency of *EGFR* mutations in solid predominant lung adenocarcinoma, *EGFR*-mutated solid subtype patients with recurrent disease had poor response to EGFR TKIs. Future studies are warranted to identify novel therapeutic targets to benefit more patients with this aggressive disease.

Methods
=======

This study included lung adenocarcinoma consecutively resected between October 2007 and May 2013 at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center. Inclusion criteria for this study were: (1) invasive lung adenocarcinoma; (2) patients underwent complete resection (lobectomy or greater extent) with curative intent. Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) were excluded. Patients who had a history of malignancy or received neoadjuvant chemotherapy were excluded. Patients who received sublobectomy (including wedge resection and segmentectomy) or palliative surgeries were also excluded.

Pathologic sections were re-reviewed by two pathologists (Yuan Li and Lei Shen), and the predominant histologic subtype of lung adenocarcinoma was recorded according to the IASLC/ATS/ERS classification system[@b1]. Clinicopathologic data collected included age, gender, smoking history, type of surgical resection, lymphovascular invasion and pathologic tumor-node-metastasis (TNM) stage according to the 7^th^ edition of the lung cancer staging system[@b18]. Local recurrence was defined as disease recurrence in the ipsilateral hemithorax and mediastinum. Distant recurrence was defined as recurrence in the contralateral lung or outside the hemithorax and mediastinum. The recurrence was defined as "distant" if both local and distant recurrences were detected within 3 months. Recurrence-free survival (RFS) and overall survival (OS) was obtained based upon follow up clinic or telephone.

RNA was extracted from frozen tumor samples, and was reverse transcribed into cDNA. Direct dideoxynucleotide sequencing was performed to detect mutations in *EGFR* (exons 18--22), *HER2* (exons 18--21), *KRAS* (exons 2--3) and *BRAF* (exons 11--15) using PCR-amplified products. The detection of *ALK*, *ROS1* and *RET* fusions was performed using a combination strategy of quantitative real-time PCR (qRT-PCR) and reverse transcriptase PCR (RT-PCR)[@b19][@b20].

NF1 mRNA expression was measured by qRT-PCR using cDNA extracted from lung adenocarcinomas harboring classic *EGFR* mutations including exon 19 deletions and L858R as well as normal lung samples. The expression level of the housekeeping gene β-actin was measured as an internal reference. Normalized expression value of NF1 was calculated using the formula: 2^\[CT\ (Normal)\ --\ CT\ (β-actin)\]\ --\ \[CT\ (Tumor)-\ CT\ (β-actin)\]^. A NF1 expression value of \> 1.0 was considered as "high expression"; otherwise, it was defined as "low expression".

The correlations between solid predominant subtype and clinicopathologic features as well as mutational status and NF1 expression levels were assessed using Pearson\'s chi-squared test or Fisher\'s exact test. Comparisons of RFS, OS or post-recurrence survival (PRS) were conducted using the Kaplan-Meier method with log-rank test in univariate analysis. Multivariate survival analysis was performed using the Cox proportional hazards regression (forward likelihood ratio model) to estimate the odds ratio (OR) and 95% confidence interval (CI). The statistical analysis was conducted in SPSS 16.0 (SPSS Inc, Chicago, Ill). All tests were two tailed, and *P* \< 0.05 was considered as statistically significant.
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###### Clinicopathologic characteristics and mutational status of solid and non-solid predominant lung adenocarcinoma

  Variable                   Solid Predominant (n = 186)   Non-Solid Predominant (n = 853)                   *P*
  ------------------------- ----------------------------- --------------------------------- --------------------------------------
  Gender                                                                                                   \< 0.001
   Female                            65 (34.9%)                      493 (57.8%)                               
   Male                              121 (65.1%)                     360 (42.2%)                               
  Age (y)                                                                                                   0.049
   ≤ 60                              112 (60.2%)                     446 (52.3%)                               
   \> 60                             74 (39.8%)                      407 (47.7%)                               
  Smoking history                                                                                          \< 0.001
   Ever                              100 (53.8%)                     244 (28.6%)                               
   Never                             86 (46.2%)                      609 (71.4%)                               
  Type of resection                                                                          \< 0.001[\*](#t1-fn1){ref-type="fn"}
   Lobectomy                         160 (86.0%)                     809 (94.8%)                               
   Bi-lobectomy                       13 (7.0%)                       36 (4.2%)                                
   Pneumonectomy                      13 (7.0%)                       8 (0.9%)                                 
  Tumor size (cm)                                                                                          \< 0.001
   ≤ 3.0                             81 (43.5%)                      668 (78.3%)                               
   \> 3.0                            105 (56.5%)                     185 (21.7%)                               
  N status                                                                                                 \< 0.001
   N0                                77 (41.4%)                      568 (66.6%)                               
   N1/N2                             109 (58.6%)                     285 (33.4%)                               
  Stage                                                                                                    \< 0.001
   I                                 54 (29.0%)                      526 (61.7%)                               
   II-III                            132 (71.0%)                     327 (38.3%)                               
  Lymphovascular invasion                                                                                  \< 0.001
   Present                           43 (23.1%)                      111 (13.0%)                               
   Absent                            143 (76.9%)                     742 (87.0%)                               
  Mutational status                                                                                            
   *EGFR* mutations                  71 (38.2%)                      570 (66.8%)                           \< 0.001
   *KRAS* mutations                  23 (12.4%)                       52 (6.1%)                             0.003
   *HER2* mutations                   2 (1.1%)                        17 (2.0%)                             0.553
   *BRAF* mutations                   3 (1.6%)                        11 (1.3%)                             1.000
   *ALK* fusions                      9 (4.8%)                        38 (4.5%)                             0.819
   *ROS1* fusions                     2 (1.1%)                        6 (0.7%)                              0.639
   *RET* fusions                      6 (3.2%)                        7 (0.8%)                              0.017
   Unknown                           70 (37.6%)                      152 (17.8%)                           \< 0.001
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\**P* value was calculated comparing lobectomy with bi-lobectomy/pneumonectomy.

###### Independent predictors of overall survival, post-recurrence survival of all patients and survival outcome of stage II-III patients undergoing adjuvant chemotherapy in multivariate analysis

  Overall Survival: All patients                                                 
  -------------------------------- --------------------- ------- --------------- ----------
  Histology                         Solid vs. Non-solid   1.876   1.245--2.825     0.003
  Pathologic stage                  Stage II/III vs. I    7.243   3.904--13.438   \< 0.001
  Lymphovascular invasion           Present vs. Absent    1.606   1.020--2.529     0.041
  *HER2* mutations                  Present vs. Absent    2.526   1.087--5.870     0.031

  Overall Survival: Stage II-III patients undergoing adjuvant chemotherapy                                                
  -------------------------------------------------------------------------- --------------------- ------- -------------- -------
  Histology                                                                   Solid vs. Non-solid   2.020   1.291--3.158   0.002
  Lymphovascular invasion                                                     Present vs. Absent    1.785   1.100--2.895   0.019
  *HER2* mutations                                                            Present vs. Absent    2.658   1.125--6.277   0.026

  Post-Recurrence Survival: All patients                                               
  ---------------------------------------- -------------------- ------- -------------- -------
  Pathologic stage                          Stage II/III vs. I   2.248   1.227--4.117   0.009
  *EGFR* mutations                          Present vs. Absent   0.609   0.409--0.906   0.015
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Abbreviations: OR, odds ratio; CI, confidence interval.

Abbreviations: OR, odds ratio; CI, confidence interval.

Abbreviations: OR, odds ratio; CI, confidence interval.

###### Data of *EGFR*-mutated solid predominant lung adenocarcinoma patients who were treated with EGFR TKIs after disease recurrence

  No.    Age (y)   Sex   Smoking History   Stage   Mutation   EGFR TKIs   Response
  ----- --------- ----- ----------------- ------- ---------- ----------- ----------
  1        59       F         Never        IIIA    E19 del    Gefitinib      PD
  2        54       F         Never         IA     E19 del    Gefitinib      PR
  3        61       F         Never        IIIA     L858R     Gefitinib      PD
  4        52       M         Ever         IIIA     L858R     Erlotinib      SD
  5        58       F         Never        IIIA     L858R     Gefitinib      PD
  6        61       M         Ever         IIIA     L858R     Gefitinib      SD
  7        56       F         Never        IIIA    E19 del    Gefitinib      PR
  8        55       F         Never         IB     E19 del    Gefitinib      PR

Abbreviations: F, female; M, male; E19 del, exon 19 deletions; TKIs, tyrosine kinase inhibitors; PR, partial response; SD, stable disease; PD, progressive disease.

[^1]: These authors contributed equally to this work.
